Organovo Holdings, Inc.'s Presentations Now Available for On-Demand Viewing at VirtualInvestorConferences.com
Company invites individual and institutional investors to log-on to VirtualInvestorConferences.com to view presentations
LINK to the company update presentation: http://virtualinvestorconferences.com > red "register / watch presentations here" button.
For investors not yet familiar with the company and desire background, including an understanding of the 3D bioprinting technology used by
Recent Company Highlights Include:
- Named one of The World's Top 10 Most Innovative Companies of 2015 in Health Care by
Fast Company , a top-tier outlet focused on business and innovation. - Formed collaboration with Yale School of Medicine to develop 3-D organ tissues for surgical transplantation research
- Commercially released the exVive3D™ Liver, Bioprinted Human Tissues for preclinical drug toxicology testing
- The exVive3D Liver selected as one of the Top 10 Innovations of 2014 by The Scientist magazine, a well-respected news outlet for life science researchers
- Won the Diagnostics & Research Tools category for the 2014 Most Innovative New Product Awards, sponsored by CONNECT
- Recognized as a 2015 Technology Pioneer by the
World Economic Forum for the ability to harness creativity to design and create transformative solutions - Appointed
Kirk Malloy , Ph.D., Senior Vice President and General Manager of Life Sciences atIllumina , to the Company's Board of Directors - Key opinion leader reported
Organovo's exVive3D Liver was able to establish the toxicity of toxic drug known to induce liver injury in humans that did not show toxicity in animal and other pre-clinical testing, an achievement historically unmet by animal models or other liver cell model systems - Initiated contracting for toxicity testing using its exVive3D Liver, for selected clients, in advance of its scheduled commercial release
- Entered into additional agreements to utilize 3D bio-printed tissue in drug discovery settings
- Reported that its 3D bioprinted breast cancer tissues enabled researchers to make compartment-specific assessments (i.e., epithelium, stroma, vasculature) of drug response — something that is not currently possible outside of in vivo models to date
- Announced an agreement with the
University of Queensland directed toward development of source cell lines for 3D kidney tissue bioprinting activities - Appointed
Gregory T. Lucier , former Chairman and CEO of Life Technologies, as a corporate advisor
About
Sign up for email updates and connect with us on Twitter (@
About VirtualInvestorConferences.com
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/organovo-holdings-incs-presentations-now-available-for-on-demand-viewing-at-virtualinvestorconferencescom-300046606.html
SOURCE